Medication delivery can vary significantly depending on the pMDI/spacer system which will have implications on the carbon footprint. In this case, the use of the AeroChamber Plus* Flow-Vu* spacer could potentially reduce the carbon footprint by up to five-fold compared to other spacers.
The most efficient and effective delivery method remains that recommended in the device IFU (one actuation inhaled at a time, as well inhalation as soon as possible after actuation)
However, this laboratory-based study has indicated that a modified common-canister protocol with an anti-static VHC as the aerosol transfer vehicle has the potential to be a viable ‘off-label’ proposition in hospital situations where there is an urgent need to conserve pMDI medication as well as avoid cross-contamination from pathogenic viruses or bacteria
The FRI deposition profiles highlight that the MDI/AeroChamber Plus* Flow-Vu* VHC delivered a significantly greater percentage of drug to the lung region than either of the two DPIs, irrespective of flow rate.
This was reflected in much higher modelled oropharyngeal deposition for the two DPIs.
The influence of inhalation flow profile was significant for one of the DPIs.
While it’s one of the most anticipated seasons of the year, summer can also be the most difficult season for Canadians living with COPD (chronic obstructive pulmonary disease). We want to help you make the most of it! Here’s what you need to know about summer, and how you can enjoy yours this year.
As a medical device manufacturer, we are committed to minimizing any disruption to the supply of our products to our customers globally, during this unprecedented time with the outbreak of COVID-19.
The FRI deposition profiles highlight that the MDI/ AeroChamber Plus* Flow Vu* VHC system delivered an appreciably greater percentage of drug to the lung region than either of the two DPIs.
The influence of inhalation flow profile was less with the MDI/VHC system and differed between the two DPIs.
